

STATISTICAL ANALYSIS PLAN STUDY P15-405 (OPALE)

Version 1.0

15 February 2018

General Information

Protocol	Real World Evidence of the Effectiveness of Paritaprevir/r – Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients with Chronic Hepatitis C - An Observational Study in France - OPALE - P15-405
Document definition	Statistical Analysis Plan (SAP) – Version 1.0. 15 February 2018
Related Documents	Study Protocol, dated 10 January 2018
Document owner	IST GmbH, Soldnerstrasse 1, D-68219 Mannheim

TABLE OF CONTENTS

Page

1	INTRODUCTION	8
2	STUDY OBJECTIVES	9
3	STUDY DESIGN.....	9
3.1	Overview of Study Design and Dosing Regimen	9
3.2	Sample Size Calculation	10
4	STATISTICAL CONSIDERATIONS AND ANALYTICAL PLAN.....	11
4.1	Primary and Secondary Parameters	11
4.1.1	Primary Effectiveness Parameter	11
4.1.2	Secondary Parameters.....	11
4.2	Statistical and Analytical Methods.....	13
4.2.1	Analysis Populations and Analysis Groups.....	13
4.2.2	Definition of Baseline and Visit Time Windows.....	18
4.2.3	Handling of missing data.....	21
4.2.4	Site and Researcher Information.....	22
4.2.5	Patient Disposition.....	23
4.2.6	Baseline Characteristics	24
4.2.6.1	Socio-demographic characteristics	24
4.2.6.2	CHC disease characteristics	25
4.2.6.3	CHC treatment history	26
4.2.6.4	Co-morbidities and co-infections.....	26
4.2.6.5	CHC related and other laboratory data at baseline.....	28
4.2.7	Analyses of the Objectives.....	31
4.2.7.1	Primary Effectiveness Variable	31

4.2.7.2	Secondary Variables.....	31
4.2.8	Analyses of Safety	42
4.2.8.1	Exposure to Study Medication.....	42
4.2.8.2	Co-medication.....	43
4.2.8.3	Adverse Events.....	44
4.2.8.4	Laboratory Data	45
4.2.9	Interim Analyses	48
4.2.9.1	First Interim Analysis.....	48
4.2.9.2	Second Interim Analysis.....	49
4.2.9.3	Third Interim Analysis	50
4.2.10	Protocol Violations and Deviations.....	51
5	DATA QUALITY ASSURANCE	51
6	METHODS OF DATA ANALYSIS AND PRESENTATION	51
6.1	Analysis Data Sets	51
6.2	SAS Output Format	51
7	REFERENCES	52

GLOSSARY OF ABBREVIATIONS

AE	adverse event
APRI	AST to platelet ratio index
AFP	alfa fetoprotein
ALT	alanine-aminotransferase
AST	aspartate-aminotransferase
ANCOVA	analysis of covariance
BMI	body mass index
BMQ	beliefs medication questionnaire
CA	competent authority
CD4	cluster of differentiation 4
CHC	chronic hepatitis C
CI	confidence interval
CNI	calcineurin
CP	core population
CPFSU	core population with sufficient follow-up data
CT	computer tomography
DAA	direct-acting antiviral agent
DDI	drug-drug interaction
EC	ethics committee
EDC	electronic data capture
eCRF	electronic case report form
EMA	European Medicines Agency
EoT	end of treatment
EQ-5D-5L	EuroQol 5 dimension 5 level
FDA	Food and Drug Administration
FIB-4	Fibrosis-4 Score/Index
FIS	Fatigue Impact Scale
γ-GT	gamma-glutamyltransferase
HCC	hepatocellular carcinoma
HCP	health care provider
Hb	hemoglobin
HbA1c	hemoglobin A1c
HBV	hepatitis B virus

GLOSSARY OF ABBREVIATIONS

HCV	hepatitis C virus
HDL	high-density lipoprotein
HIV	human immunodeficiency virus
HOMA	homeostasis model assessment
HVPG	hepatic venous pressure gradient
ICMJE	International Committee of Medical Journal Editors
IEC/IRB	independent ethics committee/- review board
IgA	Immunoglobulin A
IgG	Immunoglobulin G
IgM	Immunoglobulin M
INN	international non-proprietary name
INR	international normalized ratio
LDL	low-density lipoprotein
LLoD	lower limit of detection
LLoQ	lower limit of quantification
MAH	Marketing Authorization Holder
MedDRA	Medical Dictionary for Regulatory Activities
MLR	multiple logistic regression
MRI	magnetic resonance imaging
NCP	non-core population
NS3/NS4A	nonstructural protein 3/nonstructural protein 4A
NS5A	nonstructural protein 5A
NS5B	nonstructural protein 5B
OATP	organic anion-transporting polypeptide
OLT	orthotopic liver transplant
PAM-13	Patient Activation Measure 13
paritaprevir/r	paritaprevir/ritonavir
PCR	polymerase chain reaction
PCT	Porphyria cutanea tarda
pegIFN	pegylated interferon
PRO	patient reported outcome
PT	preferred term
RBV	ribavirin

GLOSSARY OF ABBREVIATIONS

RF	rheumatoid factor
RNA	ribonucleic acid
SAE	serious adverse event
SAP	statistical analysis plan
SD	standard deviation
SDP	study designated physician
SNP	single nucleotide polymorphism
SOC	system organ class
SP	safety population
SVR	sustained virological response
SVR12	SVR at 12 weeks after EoT
SVR24	SVR at 24 weeks after EoT
SVR48	SVR at 48 weeks after EoT
TAI	total activity impairment
TP	target population
TWP	total work productivity impairment
VAS	visual analogue scale
WHO	World Health Organization
WPAI	work productivity and activity impairment
WPAI-GH	WPAI as general health measure
WPAI-SHP	WPAI modified for specific health condition

1 Introduction

The interferon-free combination regimen of paritaprevir/r and ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in randomized controlled clinical trials with strict inclusion and exclusion criteria under well controlled conditions.

The rationale for this observational study is to determine how the efficacy and safety of the ABBVIE REGIMEN as demonstrated in pivotal trials translates into real world everyday clinical settings, which means evaluating its effectiveness. Whereas efficacy can be defined as a measure of the capacity of a treatment to produce the desired effect in a controlled environment, such as in a randomized controlled trial, effectiveness is the extent to which a drug achieves its intended effect in the usual clinical setting. Effectiveness trials typically have limited exclusion criteria and will involve the broader patient populations in routine clinical practice, treated per local label, which might include patients with heterogeneous compliance patterns and patients with significant comorbid conditions and could be used to model and disseminate best practices. Effectiveness research allows for external patient-, provider-, and system-level factors and can therefore be more relevant for health-care decisions by both providers in practice and policy-makers.

This observational study is the first effectiveness research examining the ABBVIE REGIMEN ± RBV, used according to local label, under real world conditions in France in a clinical practice patient population.

During the last decade, when dual therapy with pegylated interferon (pegIFN) plus RBV was standard of care for the treatment of CHC, the discovery of predictive factors for virological response and the subsequent development of treatment algorithms marked a milestone in patient care for CHC. As a consequence, treatment could be effectively targeted to patients most likely to respond. Interestingly, many of the now well established predictors of response to pegIFN/RBV and first generation direct acting antivirals (DAAs) in combination with pegIFN/RBV were not predictive of outcome in the development trials of the ABBVIE REGIMEN ± RBV. This observational study may play an important part in bridging the data gaps. It may help identify predictive factors of response that are important in real world treatment settings and thus, could assist in further optimizing treatment with the interferon-free ABBVIE REGIMEN ± RBV in the future.

The label of the ABBVIE REGIMEN ± RBV will vary according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease. It is therefore relevant to understand the pattern of use and outcome in daily clinical practice. In addition, this study will provide data on the impact of adherence on treatment outcomes in everyday settings, which may help treating physicians to improve the management of patients under their care.

The main aim of this observational study is to provide evidence of the effectiveness of the ABBVIE REGIMEN ± RBV in a real world setting across clinical practice patient populations.

2 Study Objectives

The objectives of this study are:

Primary objective:

1. To describe in routine clinical practice the effectiveness of the interferon-free ABBVIE REGIMEN ± RBV in patients with CHC as evidenced by sustained virological response at 12 weeks after end of treatment (SVR12)

Secondary objectives:

2. To describe the pattern of real world use of the ABBVIE REGIMEN ± RBV with respect to different patient and treatment characteristics
3. To describe the tolerability of the ABBVIE REGIMEN ± RBV
4. To document the effect of the ABBVIE REGIMEN ± RBV on PROs and work productivity in the French population
5. To determine the impact of the ABBVIE REGIMEN ± RBV on healthcare resource utilization

3 Study Design

3.1 Overview of Study Design and Dosing Regimen

This is a prospective, multi-center observational study in adult patients chronically infected with HCV receiving the interferon-free ABBVIE REGIMEN ± RBV.

University centers and outpatient clinics qualified by training and experience in the management of patients with CHC participate in this study.

The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study.

After written patient authorization has been obtained, patient data including demographic data, HCV disease characteristics, co-morbidities, co-medication, treatment details, and laboratory assessments as recorded in the patient's medical records (source documentation) are documented in the electronic case report form (eCRF). Patients are observed for the duration of the ABBVIE REGIMEN therapy and for up to 24 weeks after treatment completion.


The observational period for patients receiving 8 weeks of ABBVIE REGIMEN will be max 32 weeks (8 weeks treatment and 24 weeks post treatment observation), for patients receiving 12 weeks of ABBVIE REGIMEN is max. 36 weeks (12 weeks treatment and 24 weeks post-treatment observation) and for patients receiving 24 weeks of ABBVIE REGIMEN the observational period is max. 48 weeks (24 weeks treatment and 24 weeks post-treatment observation).

Follow-up visits, treatment, procedures and diagnostic methods follow physicians' routine clinical practice. The observational study period entails the following data collection schemes, data documented are those closest to the time windows as indicated in Figure 1:

- 8-week treatment regimen: four visits plus two interim data collection windows
- 12-week treatment regimen: four visits plus two interim data collection windows
- 24-week treatment regimen: four visits plus three interim data collection windows

This schedule is based on the anticipated regular follow-up for patients undergoing treatment for CHC.

Figure 1 - Study Flowchart



3.2 Sample Size Calculation

In phase III studies investigating the ABBVIE REGIMEN \pm RBV, SVR12 rates of at least 90% were observed, even in difficult-to-treat patients (e.g. cirrhotic G1a treatment experienced patients). To describe in routine clinical practice the effectiveness of the interferon-free ABBVIE REGIMEN \pm RBV in patients with CHC a precise estimate of the SVR12 rates in the core population of this study should be achieved (see Section 4.2.1 for the definition of the core population). It is expected, that during the planned recruitment period of 18 months between 500 to 700 patients with ABBVIE REGIMEN \pm RBV can be included into this observational study.

As obvious from Table 1, if the SVR12 rate is at least 90%, then with 600 patients in the core population the width of the 95% confidence interval (CI) will be not wider than 5%. Even in the case, that only 500 patients can be included, the 95% CI will have a width of less than 5.5% for a SVR12 rate of at least 90% and about 4% for a SVR12 rate of 95%.

Table 1 Width of 95% Confidence Interval for SVR12

Number of patients	SVR12 rates	95% Confidence Interval*		
		Lower Limit	Upper Limit	Width
700	95%	93.11	96.49	3.38%
700	90%	87.53	92.12	4.59%
600	95%	92.94	96.60	3.66%
600	90%	87.32	92.28	4.97%
500	95%	92.71	96.74	4.03%
500	90%	87.03	92.49	5.46%

* exact two-sided 95% confidence interval according Clopper-Pearson

Assuming, that in total 600 patients can be enrolled, and larger subgroups consist of at least 25% of the entire group (i.e. ≥ 150 patients), then the width of the 95% CI will $\leq 10.25\%$ for a SVR12 rate of 90% and $\leq 7.70\%$ for a SVR12 rate of 95%, which is also considered sufficiently precise for subgroup analyses. In summary, a sample size of 500 to 700 evaluable patients will provide sufficient precision for the estimation of the SVR12 rates, both in the core population as well as for subgroups of at least 25% of the core population. It is furthermore, expected, that the number of patients to be excluded from the core population will be not higher than 5%, which means that about 25 additional patients should be enrolled to achieve at least 500 evaluable patients in the core population. This assumption will be verified after the enrollment of about 300 patients.

4 Statistical Considerations and Analytical Plan

4.1 Primary and Secondary Parameters

4.1.1 Primary Effectiveness Parameter

The percentage of patients achieving SVR12 (HCV RNA <50 IU/mL 12 weeks [i.e. 70 to 126 days] after the last actual dose of the ABBVIE REGIMEN).

Please note, in the study protocol no upper boundary for the time window was specified. The upper boundary of 126 days was introduced to achieve consistency with other studies investigating the ABBVIE REGIMEN \pm ribavirin (RBV) for the treatment of CHC. For the handling of missing values see section 4.2.3.

4.1.2 Secondary Parameters

The secondary effectiveness endpoints are:

- The percentage of patients with virological response (HCV RNA <50 IU/mL) at EoT (defined as last intake of ABBVIE REGIMEN or ribavirin)
- The percentage of patients with relapse (defined as HCV RNA <50 IU/mL at EoT followed by HCV RNA ≥ 50 IU/mL)

- The percentage of patients with breakthrough (defined as at least one documented HCV RNA <50 IU/mL followed by HCV RNA ≥50 IU/mL during treatment).
- Rapid virological response at week 4 (RVR 4, i.e. patients with HCV RNA < 50 IU/mL at week 4)
- Sustained virological response 24 weeks after EoT (SVR24, i.e. patients with HCV RNA < 50 IU/mL 24 weeks after EoT)
- The number and percentage of patients meeting each and any of the following SVR12 non-response categories:
 - On-treatment virologic failure (breakthrough [defined as above] or failure to suppress [each measured on-treatment HCV RNA value ≥50 IU/mL])
 - Relapse (defined as HCV RNA <50 IU/mL at EoT followed by HCV RNA ≥50 IU/mL post-treatment for subjects who complete treatment [not more than 7 days shortened])
 - Premature study drug discontinuation with no on-treatment virologic failure
 - Missing SVR12 data and/or none of the above criteria

Further secondary variables are:

- Type of treatment regimen (\pm Dasabuvir, \pm RBV, intended and actual combination, dose and duration)
- Adherence
 - Percentage of the DAA dose taken in relation to the target dose of DAA (cumulative dose taken divided by target dose in percent)
 - Percentage of the RBV dose taken in relation to the target dose of RBV (cumulative dose taken divided by target dose in percent)
 - Percentage of missed RBV treatment days in relation to the target number of RBV treatment days
- Co-morbidities and concomitant medication
- Serious and non-serious adverse events and pregnancy occurrences
- Questionnaires on PROs: Fatigue Impact Scale (FIS), EuroQol 5 dimension 5 level (EQ-5D-5L) questionnaire and work productivity and activity impairment (WPAI) questionnaire prior to treatment initiation, at EoT as well as 12 and 24 weeks after EoT
- PAM-13, BMQ
- Healthcare resource utilization
- Metabolic laboratory profile (HbA1c, fasting insulin and fasting glucose, fasting high-density lipoprotein (HDL), fasting low-density lipoprotein (LDL), fasting cholesterol and fasting triglycerides) prior to treatment initiation, and at all subsequent visits
- Cryoglobulins, immunoglobulins and porphyrin prior to treatment initiation, and at all subsequent visits

No data will be imputed for any effectiveness or safety analyses except for the analyses of the HCV RNA endpoints and PRO questionnaires (if applicable). For further details see sections 4.2.3 and 4.2.7.2.3, respectively.

4.2 Statistical and Analytical Methods

4.2.1 Analysis Populations and Analysis Groups

Population of Patients Enrolled [EP]

The population of patients enrolled comprises all patients who voluntarily sign and date an informed consent prior to inclusion into the study and data were captured in the eCRF.

Target Population [TP]

Patients will be included if the following applies:

- Age at least 18 years
- Confirmed CHC with genotype 1 and/or 4 only, receiving combination therapy with the interferon-free ABBVIE REGIMEN ± RBV. The prescribed ABBVIE REGIMEN needs to be known.
- Have voluntarily signed and dated an informed consent prior to inclusion into the study
- Must not be participating or intending to participate in a concurrent interventional therapeutic trial

Core Population [CP]

The core population is defined as all patients of the target population (TP) (definition see above), who are adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype). The following patients will be excluded from the CP:

- Patients with unknown fibrosis status
- Cirrhotic patients with genotype 1a not receiving ribavirin
- Patients with genotype 1 for whom 2DAA instead of 3DAA is prescribed
- Patients with genotype 4 not receiving RBV

(Cirrhosis will be categorized as follows: No cirrhosis/Transition to cirrhosis, Cirrhosis. Only one method should be selected by the physicians to report stage of fibrosis. Nevertheless, if there are multiple answers the following priority will be used:

1. Biopsy,
2. Non-invasive,
3. Clinical/best guess.

For biopsy as assessment method the respective categories are defined as follows:

- “No cirrhosis” is defined by “No fibrosis”, “Mild/minimal fibrosis”, “Moderate fibrosis”
- “Transition to cirrhosis” is defined by “Advanced Fibrosis”
- “Cirrhosis” is defined by “Cirrhosis”.)

Non-Core Population [NCP]

Patients in the TP who are not in the CP.

Core Population with Sufficient Follow-up [CPSFU{12, 24}]

In addition, the core population with sufficient follow-up data regarding SVR12 or SVR24, respectively, is defined as all CP patients,

- who have evaluable HCV RNA data ≥ 70 days or >126 days, respectively, after the last actual dose of the ABBVIE REGIMEN
- or a HCV RNA value ≥ 50 IU/mL at the last measurement post-baseline
- or had HCV RNA <50 IU/mL at the last measurement post-baseline, but no HCV RNA measurement ≥ 70 days or >126 days, respectively, after the last actual dose of the ABBVIE REGIMEN due to reasons related to safety (e.g. dropped out due to adverse event) or virologic failure (e.g. virologic failure such as relapse is reported in the electronic case report form (eCRF) but date and value of the corresponding HCV RNA test is missing).

This means only (1) patients who had virological response at their last on-treatment or post-treatment measurement, but had no post-treatment HCV RNA measurements ≥ 70 days or >126 days, respectively, for reasons not related to safety or effectiveness (e.g. lost-to-follow-up or patient not willing to perform an additional HCV RNA test ≥ 70 days or >126 days post-treatment, respectively) and (2) patients who had no post-baseline HCV RNA measurements for reasons not related to safety or effectiveness, and (3) patients with missing end of treatment date for reasons not related to safety or effectiveness, will be excluded from this analysis.

Safety population [SP]

The safety population is defined as all enrolled patients who received at least one dose of the ABBVIE REGIMEN. The prescribed ABBVIE REGIMEN needs to be known.

EP, TP, CP analysis groups

The EP/TP/CP analysis groups are defined according to the patient's fibrosis stage and genotype/subtype and standard summaries are structured as follows:

- Total (regardless of fibrosis stage)
 - (1) Total (regardless of genotype)
 - (2) G1 (Total)
 - (3) G1a (including mixed G1 subtypes and patients with G1 unknown subtype)
 - (4) G1b
 - (5) G4 (non-G1)
 - (6) Other/unknown genotype (*only for EP*)
- F0/F1, F2, F3 patients
 - (7) Total (regardless of genotype)
 - (8) G1 (Total)
 - (9) G1a (including mixed G1 subtypes and patients with unknown G1 subtype)
 - (10) G1b
 - (11) G4 (non-G1)
 - (12) Other/unknown genotype (*only for EP*)
- F0/F1 patients
 - (13) Total (regardless of genotype)
 - (14) G1 (Total)
 - (15) G1a (including mixed G1 subtypes and patients with unknown G1 subtype)
 - (16) G1b
 - (17) G4 (non-G1)
 - (18) Other/unknown genotype (*only for EP*)
- F2 patients
 - (19) Total (regardless of genotype)
 - (20) G1 (Total)
 - (21) G1a (including mixed G1 subtypes and patients with unknown G1 subtype)
 - (22) G1b
 - (23) G4 (non-G1)
 - (24) Other/unknown genotype (*only for EP*)
- F3 Patients
 - (25) Total (regardless of genotype)

- (26) G1 (Total)
- (27) G1a (including mixed G1 subtypes and patients with unknown G1 subtype)
- (28) G1b
- (29) G4 (non-G1)
- (30) Other/unknown genotype (*only for EP*)
- >=F4 patients
 - (31) Total (regardless of genotype)
 - (32) G1 (Total)
 - (33) G1a (including mixed G1 subtypes and patients with unknown G1 subtype)
 - (34) G1b
 - (35) G4 (non-G1)
 - (36) Other/unknown genotype (*only for EP*)
- Patients with unknown fibrosis stage
 - (37) Total (regardless of genotype)
 - (38) G1 (Total)
 - (39) G1a (including mixed subtypes and patients with unknown subtype)
 - (40) G1b
 - (41) G4 (non-G1)
 - (42) Other/unknown genotype (*only for EP*)

(HCV genotypes will be combined as follows: G1 [total], G1a*, G1b, G4 [non-G1]. * includes mixed or other G1 subtypes and patients with unknown G1 subtypes.

The fibrosis stage is defined in Table 2. The last available result is taken. If there are at least two results available within the same month (dates are only reported in the format mm.yyyy), the most severe result is used for these dates. If there is at least one date missing, the most severe result of all available results is used. The result of FibroScan can be reported in categories or continuous. In case of contradictory information the most severe result is used.)

Table 2 Fibrosis stage

Stage of fibrosis	Fibroscan (kPa)	Fibrotest	Metavir
F0/1	< 7	≤ 0.21	0
F0/1		[0.22 ; 0.27]	1
F0/1		[0.28 ; 0.31]	
F2	[7 ; 8.8[[0.32 ; 0.48]	2
F2	[8.8 ; 9.6[
F3		[0.49 ; 0.58]	3
F3		[0.59 ; 0.72]	
F3	[9.6 ; 14.6[[0.73 ; 0.74]	
F4	>= 14.6	>= 0.75	4

SP analysis groups

The SP analysis groups are defined according to the treatment regimen and patient's fibrosis stage. The standard summaries by SP groups in the safety population are as follows (if not specified otherwise):

- Total (regardless of fibrosis stage)
 - (1) Total
 - (2) 2DAA w/o RBV
 - (3) 2DAA + RBV
 - (4) 3DAA w/o RBV
 - (5) 3DAA + RBV
- F0/F1, F2, F3 patients
 - (6) Total
 - (7) 2DAA w/o RBV
 - (8) 2DAA + RBV
 - (9) 3DAA w/o RBV
 - (10) 3DAA + RBV
- F0/F1 patients
 - (11) Total
 - (12) 2DAA w/o RBV
 - (13) 2DAA + RBV
 - (14) 3DAA w/o RBV
 - (15) 3DAA + RBV
- F2 patients
 - (16) Total
 - (17) 2DAA w/o RBV
 - (18) 2DAA + RBV
 - (19) 3DAA w/o RBV
 - (20) 3DAA + RBV
- F3 patients
 - (21) Total

- (22) 2DAA w/o RBV
- (23) 2DAA + RBV
- (24) 3DAA w/o RBV
- (25) 3DAA + RBV
- \geq F4 patients
 - (26) Total
 - (27) 2DAA w/o RBV
 - (28) 2DAA + RBV
 - (29) 3DAA w/o RBV
 - (30) 3DAA + RBV
- Patients with unknown fibrosis stage
 - (31) Total
 - (32) 2DAA w/o RBV
 - (33) 2DAA + RBV
 - (34) 3DAA w/o RBV
 - (35) 3DAA + RBV

(2DAA - paritaprevir/r-ombitasvir, 3 DAA - paritaprevir/r-ombitasvir + dasabuvir, RBV – ribavirin taken, w/o RBV – no ribavirin taken)

NCP analysis groups

The summary tables for the NCP will only show the data pooled for all patients in the NCP without any subgrouping by genotype and/or fibrosis stage.

4.2.2 Definition of Baseline and Visit Time Windows

This observational study covers three documentation periods, see Figure 1. An overview of data to be collected throughout the study is summarized in Table 3.

Table 3 - Data Documentation Schedule

Assessment/ Procedure (only available data to be collected; no diagnostic or monitoring procedures to be applied to the patients apart from those of routine clinical practice)	Baseline	Treatment Period			Post-treatment (PT) Period		
		On-treatment visits	Mid treatment visit for pts receiving 24 weeks of therapy	EoT ^b	Early PT visit	SVR 12 visit	SVR 24 visit
Informed Consent	X ^a						
Demographic information	X						
IL28B	X						
Relevant CHC disease characteristics	X						
Liver fibrosis stage	X						
CHC treatment history	X						
HCV genotype and subtype	X						
HCV RNA samples	X	X	X	X	X	X	X
Clinical chemistry and hematology	X	X	X	X	X	X	X
ABBVIE REGIMEN initiation documentation	X						
ABBVIE REGIMEN adherence		X	X	X			
Concomitant medication	X	X	X	X			
Relevant medical history, co-morbidities	X						
sAE, AE and pregnancy reporting	X	X	X	X	X ^c	X ^d	X ^d
For patients receiving RBV: Evidence, in accordance with local label, that female patient or female partner of male patient is not pregnant	X						
Metabolic profile	X	X	X	X	X	X	X
Additional laboratory assessments	X	X	X	X	X	X	X
Patient questionnaires – WPAI, EQ5D-5L, FIS	X			X		X	X
Patient questionnaires – PAM-13, BMQ 18-item	X			X			
PSP evaluation		X	X	X	X	X	
Health care resource utilization	X	X	X	X			

Abbreviations: EoT = End of Treatment (at Week 8, 12 or 24 or at premature discontinuation),
PT = Post-Treatment

a Written informed consent must be obtained before any data documentation in the eCRF

b Patients who prematurely discontinue should return to the site to document EoT data

c Tolerability documentation until PT week 4

d Pregnancy reporting for patients treated with DAA plus RBV

In accordance with the non-interventional nature of the study all HCV RNA measurements will be performed at the sole discretion of the physician and all HCV RNA measurements have to be entered into the eCRF. All recorded HCV RNA values will be assigned to appropriate time points (baseline, on-treatment visits, EoT visit, post-treatment visits) as follows:

Table 4 - Analysis Time Windows for HCV RNA

Phase	Time point	Time Window
Pre-Treatment	Baseline	Last value prior to start of study treatment (i.e. \leq study day 1)
On-treatment		Study day during treatment period [#] (Study day 1 = first treatment day)
Treatment Week	4 (RVR*)	15 - 42 [^]
EoT	Actual EoT	Study day of last dose# (28 days prior to last dose - 7 days post last dose)
Post Treatment	12 weeks (SVR 12 window)	\geq 70-126 days post last dose
	24 weeks (SVR24 window)	127-210 days post last dose
	48 weeks (SVR48 window)	> 210 days post last dose

[^]values must also be \leq 7 days post last dose

\geq study day 2

*RVR = rapid virological response

All reported safety laboratory test results will be assigned to one of the time points using the time windows specified in the table below.

Table 5 - Analysis Time Windows for Safety Laboratory Data

Phase	Time point	Time Window
Pre-Treatment	Baseline	Last value prior to start of study treatment (i.e. \leq study day 1)
Treatment Weeks		Study day during treatment period (Study day 1 = first treatment day)
	4 (day 29)	15 – 42 [^]
	8 (day 57)	43 – 70 [^]
	12 (day 85)	71 – 98 [^]
	16 (day 113)	99 – 126 [^]
EoT	Actual EoT	Study day of last dose# (28 days prior to last dose - 7 days post last dose)
Post Treatment	4 weeks (28 days post last dose)	8– 56 post last dose
	12 weeks (84 days post last dose)	57 – 126 days post last dose
	24 weeks (168 days post last dose)	127 – 252 days post last dose
	48 weeks (336 days post last dose)	253 – 420 days post last dose

[^]values must also be \leq 7 days post last dose

\geq study day 2

4.2.3 Handling of missing data

No data will be imputed for any effectiveness or safety analyses except for the analyses of the HCV RNA endpoints and certain PRO endpoints. The discussion of missing data imputation for the PRO endpoints is included in section 4.2.7.2.3.

HCV RNA values will be selected for an RVR, EOTR and SVR analysis based on visit windows as defined in Table 4. When there is no HCV RNA value in a visit window based on defined visit windows, the closest values before and after the window, regardless of the value chosen for the subsequent and preceding window, will be used for the flanking imputation described below. For analysis of RVR, EOT and SVR, if a subject has a missing HCV RNA value at a post-Day 1 visit but with undetectable or unquantifiable (LLoD or LLoQ \leq 50 IU/mL) HCV RNA levels at both the preceding value and succeeding value, the HCV RNA level will be considered undetectable or unquantifiable, respectively, at this visit for this subject. In addition, if a subject has an

unquantifiable HCV RNA level at the preceding value and an undetectable HCV RNA level at the succeeding value, or vice versa, the HCV RNA level will be imputed as unquantifiable at this visit for this subject.

For analyses of RVR, subjects still missing a value for the visit after flanking imputation will be considered as a failure. For EoTR and SVR analysis, if there is no value in the appropriate window after flanking imputation but there is an HCV RNA value after the window, then it will be imputed into the EoTR or SVR window respectively. Subsequent to this flanking and backward imputation, if the HCV RNA value remains missing at a specific time point, then the subject will be considered as virological failure at this time point (i.e., not undetectable or unquantifiable).

If a subject starts another treatment for HCV, then all HCV RNA values for this subject measured on or after the start date of the new HCV treatment will be excluded from analyses. The subject will be considered a failure for summaries of viral response at all time points after the start of the new HCV treatment.

Due to the non-interventional nature of this study several different methods for determination of the HCV RNA value can be applied. For the purpose of the statistical analysis, a HCV RNA measurement is considered <50 IU/mL,

- if a PCR test was used
- and the test result is undetectable and the LLoD of the test is ≤50 IU/mL or the test result is unquantifiable (i.e. detected but below LLoQ) and the LLoQ is ≤50 IU/mL.

4.2.4 Site and Researcher Information

Data of the study sites and of the Researcher will be presented in summary tables.

The summary tables for site information will show absolute and relative frequencies for the institution type (private practice/ private hospital, general hospital, academic/ university hospital, other), the type of unit (general population, transplant, drug user, HIV/ HCV co-infection, hepatocellular carcinoma [HCC]), and the site location (urban, rural). Regarding type of unit multiple answers per site are possible.

The principle researcher experience will be summarized by presenting for each therapeutic specialty (hepatology, infectious disease, gastroenterology, internal medicine, transplant, general practitioner) the number and percentage of principle researchers, who have the specific experience. Furthermore, the number and percentage of sites with at least one researcher (i.e. including co-researcher) of the therapeutic specialty concerned and the number of HCV-infected patients typically seen per month at the site (<25, 25-50, 51-75, 76-100, >100), including the patients seen by co-researcher, will be summarized. Note: Multiple therapeutic specialties could be reported per researcher.

An overview of tables for site and researcher information is given in Table 6.

Table 6 Overview of Outputs for Site and Researcher Information

Output Title	Output Name	Short Name	Analysis Population
Site Information - <country>	tsi_<c>		Sites with patients
Researcher Experience- <country>	tre_<c>		Sites with patients

The layouts of the tables mentioned above are provided in Part II of the SAP (Table Shells).

4.2.5 Patient Disposition

The frequencies of patients belonging to the different populations (i.e. EP, TP, CP, CPSFU; SP) will be summarized by genotype and fibrosis stage and overall using the EP analysis groups as specified in section 4.2.1. The reasons for exclusion from a particular population will be also summarized in the frequency tables. Additionally, information on patient disposition will be listed.

Furthermore the frequency of patients not completing the study as defined per protocol (i.e. no HCV RNA assessment performed at least 10 weeks post-treatment), will be summarized by treatment regimen and fibrosis stage and additionally by genotype and fibrosis stage and overall for the SP and CP. The reasons for not completing the study as entered on the CRF will be displayed (i.e. failure to return, insufficient virological response (HCV RNA detectable at end of treatment, relapse post-treatment), patient never started treatment, withdrawn consent, death, other).

Additionally, the main reason for early termination of the ABBVIE regimen (AE or SAE [Physician decision], virological non-response [Physician decision], rebound or breakthrough [Physician decision], resistance to DAA [Physician decision], patient refused to continue treatment, patient withdrew consent to participate in the study, lost to follow-up, other, unknown [if actual duration is shortened for more than 7 days]) and Ribavirin (Anemia, Nausea/Vomiting, Rash, Other) will be summarized by treatment regimen and fibrosis stage and additionally by genotype and fibrosis stage and overall for the following different analysis populations: CP and SP.

Finally the study regimens assigned at baseline will be summarized (a) by genotype and fibrosis stage and (b) by genotype and pre-treatment status (treatment naïve vs treatment experienced) for CP and SP.

An overview of Tables is given in Table 7.

Table 7 Overview of Outputs for Patient Disposition

Output Title	Output Short Name	Analysis Population
Patient Disposition by Genotype and Fibrosis Stage – EP - <country>	tdis_<c>_gf_ep	Patients Enrolled
Listing of Patient Disposition - EP- <country>	ldis_<c>_ep	Patients Enrolled
Premature Termination of the Study and its Main Reason by <Treatment Regimen/ Genotype> and Fibrosis Stage - CP - <country>	tps_<c>_<t/g>f_cp	Core population
Premature Termination of the Study and its Main Reason by <Treatment Regimen/ Genotype> and Fibrosis Stage - SP - <country>	tps_<c>_<t/g>f_sp	Safety population
Premature Termination of Treatment and its Main Reason by <Treatment Regimen/ Genotype> and Fibrosis Stage - CP - <country>	tpt_<c>_<t/g>f_cp	Core population
Premature Termination of Treatment and its Main Reason by <Treatment Regimen/ Genotype> and Fibrosis Stage - SP- <country>	tpt_<c>_<t/g>f_sp	Safety population
Treatment Regimen by Genotype and Fibrosis Stage - CP - <country>	ttr_<c>_gf_cp	Core population
Treatment Regimen by Genotype and Fibrosis Stage - SP - <country>	ttr_<c>_gf_sp	Safety population
Treatment Regimen by Genotype and Pretreatment Status - CP - <country>	ttr_<c>_gpe_cp	Core population
Treatment Regimen by Genotype and Pretreatment Status - SP - <country>	ttr_<c>_gpe_sp	Safety population

The layouts of the tables mentioned above are provided in Part II of the SAP (Table Shells).

4.2.6 Baseline Characteristics

All baseline and disease characteristics will be summarized for the CP stratified by genotype and fibrosis stage and overall, in accordance with the CP analysis groups specified in section 4.2.1. Corresponding baseline summaries will be repeated for patients with a planned treatment duration of 8 weeks of the CP and for the TP. In addition, these characteristics will be summarized by cirrhosis status and treatment regimen and overall for the SP, in accordance with the SP analysis groups specified in section 4.2.1, and overall for the NCP. Summary statistics (n, mean, median, standard deviation [SD], minimum, maximum) will be generated for continuous variables (e.g. age and body mass index [BMI]). The number and percentage of patients will be presented for categorical variables (e.g. gender and race).

An overview of tables for baseline characteristics is given in Table 8.

4.2.6.1 Socio-demographic characteristics

Demographic data will be summarized in a table displaying:

- Age (continuous and grouped by 18-65, 66-84, >=85 years)
- Gender (Male, Female)
- Race/ Ethnic Origin (White/Caucasian, Black, Asian/Oriental, Native American/American Indian, Other)
- Interleukin 28B (IL28B) genotype, rs12979860 (CC, CT, TT, Unknown)
- Interleukin 28B (IL28B) genotype, rs8099917 (TT, TG, GG, Unknown)
- Height [cm]
- Weight [kg]
- BMI [kg/m²]

4.2.6.2 CHC disease characteristics

CHC disease characteristics will be summarized in a table displaying:

- Years since diagnosis of HCV infection
- Mode of HCV infection (Drug use (i.v.), Drug use (non i.v.), Sexual transmission, Occupational [HCV acquired while doing his/her job, e.g. physicians or nurses], Blood transfusion or transplantation, Perinatal, Contaminated medical device [other than i.v. drug use], Other, Unknown)
- Pretreatment status (Naïve, Experienced)
- HCV genotype and subtype (as recorded in the CRF)
- Most recent cirrhosis status (No cirrhosis, Transition to cirrhosis, Cirrhosis) [Only one method should be selected by the physicians to report stage of fibrosis. Nevertheless, if there are multiple answers the following priority will be used:
 1. Biopsy,
 2. Non-invasive,
 3. Clinical/best guess.

For biopsy as assessment method the respective categories are defined as follows:

- “No cirrhosis” is defined by “No fibrosis”, “Mild/minimal fibrosis”, “Moderate fibrosis”
- “Transition to cirrhosis” is defined by “Advanced Fibrosis”
- “Cirrhosis” is defined by “Cirrhosis”]
- Most recent fibrosis stage (F0/1, F2, F3, F4; see section 4.2.1 for definition)
- Assessment method for liver fibrosis staging (Biopsy, Non-invasive, Clinical/Best guess) [If multiple answers are ticked, the priority is as follows: biopsy, non-invasive, clinical/best guess.]
- Time between treatment start and biopsy assessment [months] (continuous)
- Time since biopsy [months] (categorized as ≤3, >3-6, >6-12, >12-24, >24-60, >60 months)
- Metavir fibrosis score (0, 1, 2, 3, 4)
- Ishak fibrosis score (0, 1, 2, 3, 4, 5, 6)
- Batts/Ludwig fibrosis score (0, 1, 2, 3, 4)
- Knodell fibrosis score (0, 1, 3, 4)
- Scheuer fibrosis score (0, 1, 2, 3, 4)
- Time between treatment start and FibroScan assessment [months] (continuous)
- Time since FibroScan [months] (categorized as ≤1, >1-2, >2-6, >6-12, >12-24, >24 months)

- FibroScan [kPa] (<7, 7-<8.8, 8.8-<9.6, 9.6-<14.6, ≥14.6)
- Time between treatment start and ARFI assessment [months] (continuous)
- Time since ARFI [months] (categorized as ≤1, >1-2, >2-6, >6-12, >12-24, >24 months)
- AFRI [m/s]
- Time between treatment start and FibroTest assessment [months] (continuous)
- Time since FibroTest [months] (categorized as ≤1, >1-2, >2-6, >6-12, >12-24, >24 months)
- Results of FibroTest (<=0.21, 0.22-0.27, 0.28-0.31, 0.32-0.48, 0.49-0.58, 0.59-0.72, 0.73-0.74, >=0.75)
- Esophageal varices (Yes, No, Unknown)
- History of liver decompensation (No - never decompensated, Yes - but currently compensated, Yes – still decompensated [including patients with a Child Pugh Score >=7], Current signs/symptoms – Total, Current signs/symptoms – Coagulopathy, Current signs/symptoms – Hyperbilirubinemia, Current signs/symptoms – Hepatic encephalopathy, Current signs/symptoms – Hypo-albuminemia, Current signs/symptoms – Ascites, Current signs/symptoms – Bleeding from esophageal varices [multiple answers are possible])
- Child Pugh Score (categorized as 5-6, 7-9, 10-15)

4.2.6.3 CHC treatment history

For treatment-experienced patients the most recent prior treatment and the outcome to prior treatment as reported by the investigator in the eCRF (Null response, Partial response, Breakthrough, Relapse, Sustained virological response (SVR) followed by reinfection, Discontinued [and none of the above], Unknown/ None of the above) will be summarized in frequency tables. In addition to the frequency of each medication (IFN alpha, PEG IFN-alpha, IFN NOS, PEG IFN NOS, Ribavirin, DAA), the frequency of the combinations (pegIFN alpha + RBV, pegIFN alpha + RBV + Telaprevir, XXX) will be summarized.

4.2.6.4 Co-morbidities and co-infections

A summary table will present the absolute and relative frequencies of HCV co-infections, CHC related comorbidities and other co-morbidities, in more detail:

- HCV Co-infections
 - Human immunodeficiency virus (HIV)
 - Hepatitis B virus (HBV)
 - Tuberculosis
 - Schistosomiasis
- Liver and/ or CHC related co-morbidities
 - Liver transplantation
 - Hepatocellular carcinoma
 - Steatosis (non-alcoholic)

- Alcoholic liver disease
- Primary biliary cirrhosis
- Auto-immune hepatitis
- Wilson disease
- Cryoglobulinemia
- Porphyria cutanea tarda (PCT)
- Auto-immune skin disease
- Other co-morbidities
 - Kidney transplant
 - Chronic kidney disease (Mild, Moderate, Severe, Currently on dialysis, Currently not on dialysis)
 - Psychiatric disorders (Depression, Bipolar disorder, Schizophrenia, Personality disorder)
 - Diabetes mellitus (Type 1, Type 2)
 - Insulin resistance
 - Metabolic syndrome
 - Lipid disorder
 - Hyperthyroidism
 - Hypothyroidism
 - Cardiovascular disease (Myocardial infarction, Angina pectoris, Hypertension, Stroke)
 - Immunologically mediated disease
 - Hemophilia
 - Thalassemia
 - Sickle cell anemia
 - V. Willebrand disease
 - Psychoactive substance dependency (Active injection drug use, Inhalate cocaine, Marihuana/ cannabis, Opiate substitution)
 - Other

The patient's alcohol consumption will be displayed in a further table, i.e.:

- Alcohol use (None, Yes – occasional, Yes – regular, Ex-drinker [6 units/drinks per day, none in the last 3 months])
- Average number of units/drinks per week (if regular alcohol use is reported)

One unit/drink is defined as 10 milliliters (or approximately 8 grams) of pure alcohol and equals: 200 ml of beer or 100 ml of wine or 20 ml of hard liquor.

4.2.6.5 CHC related and other laboratory data at baseline

The laboratory data at baseline are the most recent available data prior to first administration of the ABBVIE REGIMEN (including day 1, see Table 5). All reported clinical laboratory test results will be assigned to one of the time points using the time windows specified in the Table 5.

A summary table will show CHC related laboratory data at baseline, i.e. HCV RNA in IU/mL, HCV RNA in log10 IU/mL, and HCV RNA categorized using 400,000, 800,000, 6,000,000 and 10,000,000 as cut-offs, ALT, ALT ratio, AST, AST ratio, APRI, FIB-4. ALT-ratio, AST ratio, APRI and FIB-4 will be calculated as follows:

ALT ratio = ALT value / upper limit of normal (ULN) of local laboratory

AST ratio = AST value / ULN of local laboratory

APRI = $100 \times \text{AST} [\text{IU/L}] / (\text{ULN of AST} [\text{IU/L}] * \text{Platelets} [10^9/\text{L}])$ (APRI= aspartate aminotransferase to platelet ratio index [1]; calculated, if laboratory assessments took place within 30 days)

FIB-4 = $(\text{Age} [\text{years}] \times \text{AST} [\text{IU/L}]) / (\text{Platelets} [10^9/\text{L}] * \text{Square root of ALT} [\text{IU/L}])$ (FIB-4= Fibrosis 4 index [2]; calculated, if laboratory assessments took place within 30 days)

In addition the following other key laboratory data at baseline will be summarized: γ-GT, total bilirubin, albumin, creatinine, creatinine clearance (continuous and categorize as Grade 1 [60-<LLN mL/min], Grade 2 [30-<60 mL/min], Grade 3 [15-<30 mL/min], Grade 4 [<15 mL/min]; if LLN is missing 75 mL/min is used), AFP, hemoglobin, platelets, prothrombin time, and INR (if documented instead of prothrombin time). The creatinine clearance will be calculated as follows:

Creatinine clearance [ml/min] = $(140-\text{age}) * \text{Weight} (\text{in kg}) * \text{constant} / \text{Creatinine} (\text{in } \mu\text{mol/L})$ (constant is 1.23 for men and 1.04 for women; calculated by Cockcroft-Gault-Formula)

A further table CD4 and HIV-RNA test results are displayed for patients with HIV only.

Table 8 Overview of Outputs for Baseline Characteristics

Output Title	Output Short Name	Analysis Population
Socio-demographic Characteristics by Genotype and Fibrosis Stage - CP - <country>	tdm_<c>_gf_cp	Core population
Socio-demographic Characteristics by Genotype and Fibrosis Stage in Patients with a Planned Treatment Duration of 8 Weeks - CP - <country>	tdm_<c>_gf_cp_wk8	Core population: patients with a planned treatment duration of 8 weeks
Socio-demographic Characteristics by Genotype and Fibrosis Stage - TP - <country>	tdm_<c>_gf_tp	Target population
Socio-demographic Characteristics by Treatment Regimen and Fibrosis Stage - SP - <country>	tdm_<c>_tf_sp	Safety population
Socio-demographic Characteristics - NCP - <country>	tdm_<c>_ncp	Non-core population
CHC Disease Characteristics by Genotype and Fibrosis Stage - CP - <country>	tdc_<c>_gf_cp	Core population
CHC Disease Characteristics by Genotype and Fibrosis Stage in Patients with a Planned Treatment Duration of 8 Weeks - CP - <country>	tdc_<c>_gf_cp_wk8	Core population: patients with a planned treatment duration of 8 weeks
CHC Disease Characteristics by Genotype and Fibrosis Stage - TP - <country>	tdc_<c>_gf_tp	Target population
CHC Disease Characteristics by Treatment Regimen and Fibrosis Stage - SP - <country>	tdc_<c>_tf_sp	Safety population
CHC Disease Characteristics - NCP - <country>	tdc_<c>_ncp	Non-core population
CHC Related Laboratory Variables at Baseline by Genotype and Fibrosis Stage - CP - <country>	tlcdb_<c>_gf_cp	Core population
CHC Related Laboratory Variables at Baseline by Genotype and Fibrosis Stage in Patients with a Planned Treatment Duration of 8 Weeks - CP - <country>	tlcdb_<c>_gf_cp_wk8	Core population: patients with a planned treatment duration of 8 weeks
CHC Related Laboratory Variables at Baseline by Genotype and Fibrosis Stage - TP - <country>	tlcdb_<c>_gf_tp	Target population
CHC Related Laboratory Variables at Baseline by Treatment Regimen and Fibrosis Stage - SP - <country>	tlcdb_<c>_tf_sp	Safety population
CHC Related Laboratory Variables at Baseline - NCP - <country>	tlcdb_<c>_ncp	Non-core population
Other Key Laboratory Variables at Baseline by Genotype and Fibrosis Stage - CP - <country>	tkldb_<c>_gf_cp	Core population
Other Key Laboratory Variables at Baseline by Genotype and Fibrosis Stage in Patients with a Planned Treatment Duration of 8 Weeks - CP - <country>	tkldb_<c>_gf_cp_wk8	Core population: patients with a planned treatment duration of 8 weeks

Other Key Laboratory Variables at Baseline by Genotype and Fibrosis Stage - TP - <country>	tkldb_<c>_gf_tp	Target population
Other Key Laboratory Variables at Baseline by Treatment Regimen and Fibrosis Stage - SP - <country>	tkldb_<c>_tf_sp	Safety population
Other Key Laboratory Variables at Baseline - NCP - <country>	tkldb_<c>_ncp	Non-core population
CHC Treatment History in Treatment Experienced Patients by Genotype and Fibrosis Stage - CP - <country>	tth_<c>_gf_cp_exp	Core population: treatment-experienced patients
CHC Treatment History in Treatment Experienced Patients with a Planned Treatment Duration of 8 Weeks by Genotype and Fibrosis Stage - CP - <country>	tth_<c>_gf_cp_expwk8	Core population: patients with a planned treatment duration of 8 weeks
CHC Treatment History in Treatment Experienced Patients by Genotype and Fibrosis Stage - TP - <country>	tth_<c>_gf_tp_exp	Target population: treatment-experienced patients
CHC Treatment History in Treatment Experienced Patients by Treatment Regimen and Fibrosis Stage - SP - <country>	tth_<c>_tf_sp_exp	Safety population: treatment-experienced patients
CHC Treatment History in Treatment Experienced Patients - NCP - <country>	tth_<c>_ncp_exp	Non-core population: treatment-experienced patients
Co-morbidities and Co-infections by Genotype and Fibrosis Stage - CP - <country>	tcoi_<c>_gf_cp	Core population
Co-morbidities and Co-infections by Genotype and Fibrosis Stage in Patients with a Planned Treatment Duration of 8 Weeks - CP - <country>	tcoi_<c>_gf_cp_wk8	Core population: patients with a planned treatment duration of 8 weeks
Co-morbidities and Co-infections by Genotype and Fibrosis Stage - TP - <country>	tcoi_<c>_gf_tp	Target population
Co-morbidities and Co-infections by Treatment Regimen and Fibrosis Stage - SP - <country>	tcoi_<c>_tf_sp	Safety population
Co-morbidities and Co-infections - NCP - <country>	tcoi_<c>_ncp	Non-core population
Alcohol Consumption by Genotype and Fibrosis Stage - CP - <country>	tac_<c>_gf_cp	Core population
Alcohol Consumption by Genotype and Fibrosis Stage in Patients with a Planned Treatment Duration of 8 Weeks - CP - <country>	tac_<c>_gf_cp_wk8	Core population: patients with a planned treatment duration of 8 weeks
Alcohol Consumption by Genotype and Fibrosis Stage - TP - <country>	tac_<c>_gf_tp	Target population
Alcohol Consumption by Treatment Regimen and Fibrosis Stage - SP - <country>	tac_<c>_tf_sp	Safety population
Alcohol Consumption - NCP - <country>	tac_<c>_ncp	Non-core population
CD4 and HIV RNA in Patients with HIV at Baseline by Genotype and Fibrosis Stage - CP - <country>	tlchb_<c>_gf_cp_hiv	Core population: patients with HIV

CD4 and HIV RNA in Patients with HIV at Baseline and a Planned Treatment Duration of 8 Weeks by Genotype and Fibrosis Stage - CP - <country>	tlchb_<c>_gf_cp_hiv_wk8	Core population: patients with a planned treatment duration of 8 weeks
CD4 and HIV RNA in Patients with HIV at Baseline by Genotype and Fibrosis Stage - TP - <country>	tlchb_<c>_gf_tp_hiv	Target population: patients with HIV
CD4 and HIV RNA in Patients with HIV at Baseline by Treatment Regimen and Fibrosis Stage - SP - <country>	tlchb_<c>_tf_sp_hiv	Safety population: patients with HIV
CD4 and HIV RNA in Patients with HIV at Baseline - NCP - <country>	tlchb_<c>_ncp_hiv	Non-core population: patients with HIV

The layouts of the tables mentioned above are provided in Part II of the SAP (Table Shells).

4.2.7 Analyses of the Objectives

4.2.7.1 Primary Effectiveness Variable

The primary objective of this study is to estimate the SVR12 rates in HCV patients treated according to the ABBVIE regimen.

Therefore the simple percentage of patients achieving SVR12 (for definition see section 4.1.1) will be calculated and a two-sided 95% confidence interval (CI) of the percentage will be computed based on the Wilson's Score method.

The primary effectiveness analysis on clinical outcomes will be performed on all patients in the CP stratified by genotype and fibrosis stage and overall.

In the framework of sensitivity analyses the primary analyses will be repeated for the CPSFU. Furthermore, the SVR12 rates will be also determined for all patients of the NCP.

An overview of Tables is given in Table 9.

The layouts of the tables mentioned above are provided in Part II of the SAP (Table Shells).

4.2.7.2 Secondary Variables

4.2.7.2.1 Secondary Effectiveness Variables

Response

For the other response rates (i.e. RVR, SVR24, EoT response rate, relapse rate, viral breakthrough), the simple percentage of patients and a two-sided 95% confidence interval (CI) of the percentage will be computed (based on the Wilson's score method) as well. The RVR and EoT response rates will be reported for CP and the SVR24 rates will be reported for the respective CPSFU, stratified by genotype and fibrosis stage and overall. The relapse rates will be estimated stratified by SVR window (i.e. during SVR12 window=relapse₁₂, during SVR24 window=relapse₂₄, after SVR24 window=relapse_{late}) and stratified by genotype and fibrosis stage and overall in patients of the CP with EoT response who fulfilled the following criteria:

- completed treatment as defined previously,

- had at least one HCV RNA measurement ≥ 70 days post-treatment or was a treatment failure between EoT and 70 days post-treatment.

Viral breakthrough rates [defined as at least one documented HCV RNA <50 IU/mL followed by HCV RNA ≥ 50 IU/mL during treatment] will be estimated overall and stratified by genotype and fibrosis stage in all patients of the CP, who have at least one undetectable or unquantifiable, on-treatment HCV RNA measurement and at least one on-treatment or EoT measurement thereafter.

Non-Response

In another table, the numbers and the percentages of the SVR12 non-responder categories and responder will be summarized for CP patients, overall and stratified by genotype and fibrosis stage. The following SVR12 non-response categories will be considered:

- On-treatment virologic failure (breakthrough [defined as at least one documented HCV RNA <50 IU/mL followed by HCV RNA ≥ 50 IU/mL during treatment] or failure to suppress [each measured on-treatment HCV RNA value ≥ 50 IU/mL])
- Relapse (defined as HCV RNA <50 IU/mL at EoT followed by HCV RNA ≥ 50 IU/mL post-treatment and completed treatment as defined previously)
- Death and none of the above
- Premature study drug discontinuation with no on-treatment virologic failure and none of the above
- Insufficient virological response, other than those mentioned above (patients for whom insufficient virological response was reported, or who had HCV RNA ≥ 50 IU/mL post EoT) and none of the above
- Missing SVR12 data and/or none of the above criteria

Virological response rates and non-response categories will be displayed for patients who completed treatment with ABBVIE regimen, as well. Furthermore, virological response rates will be displayed for patients with a planned treatment duration of 8 weeks.

SVR12 (Exploratory Analyses)

Univariate and multiple logistic regression (MLR) methods will be used to investigate the impact of various explanatory covariates (patient and disease characteristics) at baseline on SVR12.

These analyses will be of exploratory nature, data driven, and will be performed for CP population. Univariate logistic regression will be performed first and then backward selection procedures will be applied to generate the final MLR model. A p-value <0.05 will be used for the covariates to stay in the model in a backward elimination step. If the percentage of patients with available data for a variable is lower than 80% of the patient group analyzed, then this variable will not be considered in the MLR analysis.

The variables to be considered are as follows:

- Key demographic information
 - Age (continuous)
 - Gender (Female [reference], Male)

- Race/ethnic origin (White/Caucasian [reference], Black, Asian/Oriental, Other [all other races]); at least two categories with at least 10% of the patients each have to exists, so that this variable will be considered
- Weight (continuous)
- BMI (continuous)
- IL28B, rs12979860 (CC [reference], CT or TT); patients with unknown genotype are excluded from the respective analyses.
- CHC disease characteristics
 - Years since diagnosis (continuous)
 - Mode of CHC infection (Drug use [reference], Other [all other answers excluding unknown], unknown);
 - Most recent cirrhosis status (No cirrhosis/Transition to cirrhosis [reference], Cirrhosis; for definition see section 4.2.6.2)
- HCV RNA level at baseline (\log_{10} IU/mL)
- HCV genotype(G1a*, G1b, G4; for definition see section 4.2.6.2)
- Type of treating institute (Private Practice / Private Hospital, Academic / University Hospital, General Hospital, Other)
- Co-infections (every patient not reporting the respective co-infection is considered as not having the respective co-infection)
 1. HIV(No [reference], Yes)
 2. HBV(No [reference], Yes)
- Liver and/or CHC related co-morbidities (every patient not reporting the respective co-morbidity is considered as not having the respective co-morbidity)
 1. Liver transplantation (No [reference], Yes)
 2. Steatosis (non-alcoholic) (No [reference], Yes)
 3. Decompensated liver disease (No [reference], Yes)
- Other co-morbidities (every patient not reporting the respective co-morbidity is considered as not having the respective co-morbidity)
 1. Depression (No [reference], Yes)
 2. Diabetes mellitus (No [reference], Type 1/Type 2)
 3. Hypertension (No [reference], Yes)
 4. Immunologically mediated disease (No [reference], Yes)
 5. Hypothyroidism (No [reference], Yes)

- Alcohol use (None [reference], Yes –occasional, Yes –regular, Exdrinker)
- Key clinical chemistry and hematology laboratory variables at baseline
 1. ALT ratio (continuous, see 4.2.6.5)
 2. AST ratio (continuous, see 4.2.6.5)
 3. Platelets [$10^9/L$] (continuous)
- Prior treatment status (HCV treatment naïve [reference], HCV treatment experienced)

Additionally, an interaction term for cirrhosis status and genotype will be considered. If the most recent stage of liver fibrosis status (No cirrhosis/Transition to cirrhosis vs Cirrhosis), the genotype (G4, G1b vs G1a) or the interaction of both remains in the final model, then additional MLR might be considered for the subgroups concerned, taking into account the treatment regimen (e.g. in cirrhotic G1 patients: RBV vs no RBV and 8 wks, 12 wks vs 24 weeks).

The categories pre-specified above could be modified in the analyses if this is supported by the data (e.g. categories could be combined, if their impact on SVR12 is similar). Furthermore, continuous variables can be replaced by categorical variables.

Adherence

Adherence will be displayed for the CP by genotype and fibrosis stage and for the SP by treatment regimen and fibrosis stage. Summary statistics (n, mean, median, standard deviation [SD], and range) will be generated for continuous variable. Numbers and percentages of patients will be presented for categorical variables.

- Adherence to ABBVIE regimen (% of target dose [adherence=cumulated number of pills taken / (initial prescribed number of pills x planned duration)])
 - >105%
 - >95%-<=105%
 - >80%-<=95%
 - >50%-<=80%
 - <=50%
- Adherence to ribavirin (% of target dose [adherence=cumulated dose taken / (initial prescribed dose x planned duration)])

- >105%
 - >95%-<=105%
 - >80%-<=95%
 - >50%-<=80%
 - <=50%
- Percentage of actual treatment duration in relation to the target duration of ABBVIE regimen taken
- Deviating duration of ABBVIE regimen
 - Early discontinuation (actual duration is shortened for more than 7 days)
 - Not deviated
 - Exceedance (actual duration is prolonged for more than 7 days)
- Method used to document adherence (Interview, Diary)
- Percentage of actual days with treatment with RBV in relation to the planned duration
- Ribavirin earlier discontinued than ABBVIE regimen
- Initial dose of Ribavirin
 - 1000 mg/day
 - 1200 mg/day
 - XXX
- Cumulative dose of Ribavirin (g)
- Dose modifications/termination of RBV [in patients taking RBV, for a patient more than one dose modification and its main reason could be reported, but for each single reason the patient is counted only once] (Total number of patients with lower dose than highest previous dose [including patients who stopped the treatment earlier], Anemia, Nausea/Vomiting, Rash, Other [including patients who discontinued ABBVIE regimen earlier, but did not stop the RBV treatment before the ABBVIE regimen])

In addition to the summary statistics of the adherence variables, logistic regression analyses will be performed for the following adherence variables: "adherence to ABBVIE regimen" in all patients of the CP, "adherence to ribavirin" in all patients of the CP taking RBV, each categorized as follows: >=95%, >80%-<=95%, <=80% to investigate the additional impact of overall treatment adherence on SVR12. The categories may be changed if they are sparsely filled. Adherence will be included as mandatory covariate in addition to the baseline explanatory variables already mentioned above. Also the same methods will be applied as described above.

An overview of Tables is given in Table 9.

Table 9 Overview of Outputs for Primary and Secondary Effectiveness Analysis

Output Title	Output Short Name	Analysis Population
Virological Response Rates by Genotype and Fibrosis Stage – CP/CPSFU - <country>	tvr_<c>_gf_cp	Core population/ Core population with sufficient follow-up data
Virological Response Rates by Genotype and Fibrosis Stage in Patients who Completed ABBVIE Regimen – CP/CPSFU - <country>	tvr_<c>_gf_cp_ARC	Core population/ Core population with sufficient follow-up data: patients who completed ABBVIE regimen
Virological Response Rates by Genotype and Fibrosis Stage in Patients with a Planned Treatment Duration of 8 Weeks – CP/CPSFU - <country>	tvr_<c>_gf_cp_wk8	Core population/ Core population with sufficient follow-up data: patients with a planned treatment duration of 8 weeks
Virological Response Rates – NCP - <country>	tvr_<c>_ncp	Non-core population
Relapse Rates by Genotype and Fibrosis Stage – CP - <country>	trr_<c>_gf_cp	Core population
Viral Breakthrough by Genotype and Fibrosis Stage – CP - <country>	tvb_<c>_gf_cp	Core population
Non-Response Rates by Genotype and Fibrosis Stage – CP - <country>	tnrr_<c>_gf_cp	Core population
Non-Response Rates by Genotype and Fibrosis Stage in Patients who Completed ABBVIE Regimen – CP - <country>	tnrr_<c>_gf_cp_ARC	Core population: patients who completed ABBVIE regimen
Impact of Patient and Disease Characteristics on SVR12 – CP - <country>	tis_<c>_cp	Core population
Adherence by Genotype and Fibrosis Stage - CP - <country>	tah_<c>_gf_cp	Core population
Adherence by Treatment Regimen and Fibrosis Stage - SP - <country>	tah_<c>_gf_sp	Safety population
Impact of Adherence to ABBVIE Regimen on SVR12 – CP - <country>	tiaa_<c>_cp	Core population
Impact of Adherence to Ribavirin on SVR12 in patients taking RBV – CP - <country>	tiar_<c>_cp_RBV	Core population: patients taking RBV

The layouts of the tables mentioned above are provided in Part II of the SAP (Table Shells).

4.2.7.2.2 Liver Fibrosis Assessment

The number and percent of patients who had FibroTest results <= 0.21, 0.22-0.27, 0.28-0.31, 0.32-0.48, 0.49-0.58, 0.59-0.72, 0.73-0.74, and >= 0.75 will be displayed by visit for the CP by genotype and fibrosis stage and for the SP by treatment regimen and fibrosis stage.

4.2.7.2.3 Quality of life

Quality of life will be analyzed for CP by fibrosis stage (F0-F3, F0/F1, F2, F3, >= F4) and treatment regimen (2DAA w/o RBV, 2DAA + RBV, 3DAA w/o RBV and 3DAA + RBV).

Assessment of Fatigue – FIS Mapi Research Institute ID-2115

The Fatigue Impact Scale (FIS) questionnaire will be used to assess the impact of fatigue on the quality of life of patients and to examine the relationship between the severity of fatigue and various parameters of the disease. The FIS questionnaire was developed to obtain validated, reliable fatigue specific measures. There are 40 items, each of which is scored 0 (no problem) to 4 (extreme problem), providing a continuous scale of 0-160. It is composed of three subscales that describe how fatigue impacts upon cognitive, physical and psychosocial functioning.

Missing data will be imputed by replacing the missing value with the median value of the respondent for the total scale. For respondents who omit more than 4 items no score will be calculated. [6]

A summary table will show descriptive statistics (n, mean, median, SD, minimum and maximum) for the total score and for the three subscales for baseline and the post-baseline time points, as well as changes from baseline, by cirrhosis status and treatment regimen. In addition, analysis of covariance (ANCOVA) will be applied to investigate the effect of the different ABBVIE REGIMENS (\pm RBV) by fibrosis stage on FIS endpoints using the corresponding FIS baseline values as covariates. Imputation of missing items will be performed as specified in the FIS manual.

Assessment of general quality of life - EQ-5D-5L

The EQ-5D-5L is a health state utility instrument that evaluates preference for health status (utility). The 5 items in the EQ-5D-5L comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which are rated on 5 levels of severity (1: indicating no problem, 2: indicating slight problems, 3: indicating moderate problems, 4: indicating severe problems, 5: indicating extreme problems), and a separate VAS

Patients' responses to the EQ-5D-5L will be combined into a unique health state using a 5-digit code with one digit from each of the 5 dimensions representing the level of severity. These EQ-5D-5L states will be converted into a single preference-weighted health utility index score by applying country-specific weights (if available) or US weights (if not available). [3]

No imputation will be performed for missing items, and in case of missing items no index score will be calculated.

A summary table will show descriptive statistics (n, mean, median, SD, minimum and maximum) of the index score values and for the VAS values for baseline and the post-baseline time points,

as well as changes from baseline, by cirrhosis status and treatment regimen. In addition, analysis of covariance (ANCOVA) will be applied to investigate the effect of the different ABBVIE REGIMENS (\pm RBV) by fibrosis stage on EQ-5D-5L endpoints at the post-baseline time points using the corresponding EQ-5D-5L baseline values as covariates.

Assessment of work productivity and activity impairment – WPAI Hep C V2.0

The WPAI questionnaire will be used to measure work absenteeism, work presenteeism, and daily activity impairment. The WPAI Hep C V2.0 is the HCV specific questionnaire that will be used in this study. Respondents are asked about time missed from work and time while at work during which productivity was impaired in the past seven days. Results of WPAI are expressed as a percentage of impairment from 0 to 100, with higher percentages indicating greater impairment and less productivity:

- % Presenteeism – percentage of impairment while working due to health problem
- % Absenteeism – percentage of work time missed due to health problem
- % Total work productivity impairment (TWP) – percentage of overall work impairment due to health problem
- % Total activity impairment (TAI) – percentage of general (non-work) activity impairment due to health problem

The WPAI Hep C v2.0 consists of 6 questions aimed at the following targets:

Q1.currently employed (yes, no)
Q2.hours missed due to hepatitis C in the last seven days
Q3.hours missed due to other reasons in the last seven days
Q4.hours actually worked in the last seven days
Q5.degree hepatitis C affected productivity while working
Q6.degree hepatitis C affected regular activities

The four scores will be derived according to the WPAI-SHP scoring manual [4] as follows:

1. % absenteeism: $100 \times Q2 / (Q2 + Q4)$
2. % presenteeism: $100 \times Q5 / 10$
3. % TWP: $100 \times \{Q2 / (Q2 + Q4) + [Q4 / (Q2 + Q4)] \times Q5 / 10\}$
4. % TAI: $100 \times Q6 / 10$

The coding rules for contradictory or missing information are:

- If Q1 = YES or Q1 = NO or missing and hours missed or worked > 0, then employed. If Q1 = missing and hours missed and worked = 0, then not employed.
- If hours worked = 0, then productivity while at work is not applicable.
- A score will be set to missing if one or more of the items Q1-6 that are needed for the calculation of the score are missing. No imputation will be performed for missing items.
- Someone who missed all work hours due to health is 100% impaired.

The summary table will present the absolute and relative frequencies of employed and unemployed patients and descriptive statistics (n, mean, median, SD, minimum and maximum) for the four scores for baseline and the post-baseline time points by fibrosis stage and treatment regimen.

4.2.7.2.4 Attitude towards self-management, medication and support

The attitude towards self-management, medication and support will be analyzed for the CP.

Patient Activation Measure – (PAM-13)

The Patient Activation Measure (PAM) 13 is a measure used to assess the patient knowledge, skill, and confidence for self-management [5]. The PAM-13 item scale is a measure used to assess the patient knowledge, skill, and confidence for self-management. Each of the 13 items can be answered with one of four possible response options, which are “disagree strongly” (1), “disagree” (2), “agree” (3), “agree strongly” (4).

The scoring will be done by Insignia Health. If there are less than nine items answered, no summary score will be calculated.

A summary table will show descriptive statistics (n, mean, median, SD, minimum and maximum) of the score for baseline and the post-baseline time points, as well as changes from baseline, by cirrhosis status and treatment regimen. In addition, analysis of covariance (ANCOVA) will be applied to investigate the effect of the different ABBVIE REGIMENS (\pm RBV) by fibrosis stage on the score using the corresponding baseline value as covariate.

Beliefs Medication Questionnaire – (18-item BMQ)

The 18-item BMQ consists of 18 questions used to screen for patients’ beliefs, attitudes and concerns about their medication. The BMQ consists of two sections, the BMQ-Specific and the BMQ-General. The BMQ-Specific section comprises two 5 item subscales assessing the necessity of and the concerns about the prescribed medication for personal use (Specific-Necessity and Specific-Concerns). The BMQ-General section comprises two 4 item subscales assessing beliefs that medicines are harmful and overused by doctors in general (General-Harm and General-Overuse). The 18 items are rated on a Likert scale from 1=strongly disagree to 5 = strongly agree and the 18 items are summarized into the 4 subscale scores. The total score of each BMQ subscale will be calculated.

If for any of these subscales one single item is missing, the subscale will be calculated as the mean of the remaining items. This corresponds to replacing the missing value by the “average” of the available answers. If more than one item is missing, the respective subscore will be considered as not evaluable.

A summary table will show descriptive statistics (n, mean, median, SD, minimum and maximum) of the four scores for baseline and the post-baseline time points, as well as changes from baseline, by cirrhosis status and treatment regimen. In addition, analysis of covariance (ANCOVA) will be applied to investigate the effect of the different ABBVIE REGIMENS (\pm RBV) by fibrosis stage on BMQ endpoints using the corresponding BMQ baseline values as covariates.

4.2.7.2.5 Treatment related health care resource utilization until EoT

Resource utilization within the four weeks prior to the start of the ABBVIE regimen and until EoT (since baseline) will be displayed for CP by genotype and fibrosis stage and for SP by treatment regimen and fibrosis stage.

Information on outpatient consultations (i.e. number of outpatient consultations [defined as sum of all visits] - continuous and categorized as 0, 1-3, 4-6, >=7), and hospitalizations (.i.e. number of hospitalization periods [defined as sum of all visits] - continuous and categorized as 0, 1, 2-3, >=4) due to liver disease until EoT (since baseline) will be summarized.

Outpatient consultations

Outpatient consultations until EoT (since baseline) will be summarized in a table. The following variables will be displayed:

- Mode of transport used
 - Personal vehicle
 - VSL (ambulance)
 - Taxi
 - Other/Unknown
- Type of consultation
 - Generalist
 - Specialist
 - Other/Unknown
- Complementary exams performed
 - HCV RNA PCR
 - Laboratory clinical chemistry
 - Laboratory clinical hematology
 - Other/Unknown
- Treatment prescribed

Table 10 Overview of Outputs for Secondary Variables

Output Title	Output Short Name	Analysis Population
FibroTest Results by Genotype and Fibrosis Stage - CP - <country>	tvf_<c>_gf_cp	Core population
FibroTest Results by Treatment Regimen and Fibrosis Stage - SP - <country>	tvf_<c>_tf_sp	Safety population
EQ-5D-5L by Treatment Regimen and Fibrosis Stage - CP - <country>	teq<a>_<c>_tf_cp	Core population
FIS by Treatment Regimen and Fibrosis Stage - CP - <country>	tfis<a>_<c>_tf_cp	Core population
WPAI by Treatment Regimen and Fibrosis Stage - CP - <country>	twp_<c>_tf_cp	Core population
PAM-13 by Treatment Regimen and Fibrosis Stage - CP - <country>	tpam<a>_<c>_tf_cp	Core population
BMQ by Treatment Regimen and Fibrosis Stage - CP - <country>	tbmq<a>_<c>_tf_cp	Core population
Outpatient Consultations and Hospitalization Until EoT by Genotype and Fibrosis Stage - CP - <country>	tohl_<c>_gf_cp	Core population
Outpatient Consultation Until EoT by Genotype and Fibrosis Stage - CP - <country>	tocl_<c>_gf_cp	Core population
Outpatient Consultations and Hospitalization Until EoT by Treatment Regimen and Fibrosis Stage - SP - <country>	tohl_<c>_tf_sp	Safety population
Outpatient Consultation Until EoT by Treatment Regimen and Fibrosis Stage - SP - <country>	tocl_<c>_tf_sp	Safety population

The layouts of the tables mentioned above are provided in Part II of the SAP (Table Shells).

4.2.8 Analyses of Safety

All safety variables will be summarized for patients in the SP using descriptive statistical methods stratified by treatment regimen and fibrosis stage and overall.

An overview of tables for the individual values is given in Table 13.

The layouts of the tables mentioned above are provided in Part II of the SAP (Table Shells).

4.2.8.1 Exposure to Study Medication

One table will show the frequencies for early discontinuation and exceedance of ABBVIE regimen or ribavirin and the corresponding reasons for SP by treatment regimen and fibrosis stage. The ABBVIE regimen is considered to have been prematurely discontinued if actual duration is shortened for more than 7 days. The duration for taking ABBVIE regimen is considered to have

been exceeded if the actual duration is prolonged for more than 7 days. Furthermore, summary statistics will be generated for the duration of ABBVIE regimen taken and the duration of ribavirin taken, i.e. n, mean, median, standard deviation [SD], minimum, maximum.

Unintended medication errors, i.e. patient missed taking Paritaprevir/r-Ombitasvir or Dasabuvir for at least 7 days in a row, will be displayed by medication for the entire treatment period.

4.2.8.2 *Co-medication*

Treatments, surgical and medical procedures will be coded by ABBVIE assigning appropriate preferred and class terms. Frequencies will be displayed for SP by treatment regimen and fibrosis stage.

In one table, the co-medication (preferred term) will be grouped by class. Only co-medication received during treatment specified by ABBVIE regimen will be displayed (Treatment profiles: A1, A2, C1 Drug B, C2 Drug B, C3 Drug B, D).

In another table, the co-medication (preferred term) will be grouped by profile. All treatment profiles will be considered, i.e.:

- A1: Continued (A1)
- A2: Permanently discontinued during CHC treatment (A2)
- A3: Permanently discontinued prior to CHC treatment (A3)
- B: Discontinued prior to CHC treatment and reintroduced post-treatment (B)
- C1 Drug A: Permanently replaced at start of CHC treatment (C1A)
- C1 Drug B: Substitute at start of CHC treatment and discontinued during CHC treatment (C1B)
- C2 Drug A: Permanently replaced at start of CHC treatment (C2A)
- C2 Drug B: Substitute at start of CHC treatment and continued (C2B)
- C3 Drug A: Replaced during CHC treatment (C3A)
- C3 Drug B: Substitute during CHC treatment (C3B)
- D: Introduced during CHC treatment (D)
- No profile reported: No profile reported

Another table will show the associated treatment profiles for the medications of special interest. Therefore the medication will be pooled appropriately. All treatment profiles will be considered.

A further table will show the associated treated conditions, i.e.:

- Alcoholic liver disease
- Angina pectoris
- Auto-immune hepatitis
- Auto-immune skin disease
- Bipolar disorder
- Chronic kidney disease
- Cryoglobulinemia
- Depression
- Diabetes mellitus (Type 1)
- Diabetes mellitus (Type 2)
- Hemophilia

- Hepatitis B
- Hepatocellular carcinoma
- HIV
- Hypertension
- Hyperthyroidism
- Hypothyroidism
- Immunologically mediated disease
- Insulin resistance
- Kidney transplantation
- Lipid disorder
- Liver transplantation
- Metabolic syndrome
- Myocardial infarction
- Opiate substitution
- Personality disorder
- Porphyria cutanea tarda (PCT)
- Primary biliary cirrhosis
- Schistosomiasis
- Schizophrenia
- Sickle cell anemia
- Steatosis (non-alcoholic)
- Stroke
- Thalassemia
- Tuberculosis
- v. Willebrand disease
- Wilson disease
- Other

All treatment profiles will be considered.

One table will displays the number of patients taking herbals except St. John's Wort, homeopathics or other drugs for which neither a name nor a profile nor a treated condition had to be reported. These medications will be excluded from the other co-medication tables.

A glossary will show the verbatim terms and the corresponding coded terms used (see Table 13).

4.2.8.3 Adverse Events

All tolerability variables will be summarized using descriptive statistical methods for the SP stratified by treatment regimen and fibrosis stage and overall.

AEs will be coded using MedDRA. A glossary will show the verbatim terms and the corresponding coded terms used (see Table 13).

The number and percentage of patients with treatment-emergent AEs (i.e. any reported event that begins or worsens in severity after initiation of study drug through 30 days post-study drug dosing including those who are related to the study drug independent of the occurrence and those where the date of onset is missing) will be tabulated by primary MedDRA SOC and PT.

Corresponding summary tables will be provided for all serious treatment-emergent AEs and additional for all non-serious treatment-emergent AEs. In the table of non-serious AEs (that must exclude any SAE) only preferred terms that occurred at a frequency of $\geq 5\%$ in any treatment group will be displayed (no SOCs will be displayed).

The tabulation of the number of patients with treatment-emergent AEs by severity (AEs by severity [mild, moderate, severe], AEs leading to death, AEs leading to hospitalization) and relationship to study drug will also be provided (ABBVIE regimen, ribavirin, medication error - paritaprevir/r-ombitasvir, medication error – dasabuvir, ABBVIE regimen withdrawn, ribavirin withdrawn).

Patients reporting more than one AE for a given MedDRA PT will be counted only once for that term using the most severe incident for the severity summary table and the most related for the relationship summary table. Patients reporting more than one type of event within a SOC will be counted only once for that SOC.

The frequency of pregnancies will be displayed as well.

4.2.8.4 Laboratory Data

All reported clinical laboratory test results will be assigned to one of the time points using the time windows specified in the Table 5. All will be performed for the SP by treatment regimen and fibrosis stage.

Changes from baseline to each post-baseline visit will be summarized descriptively (N, mean, SD, median, minimum, maximum). A summary table will show laboratory hematology. In other tables, information about clinical chemistry and the metabolic profile will be summarized. Therefore the HOMA-Index (Homeostasis Model Assessment) is calculated as follows:

$$\text{HOMA-Index} = \text{Insulin (fasting, in } \mu\text{U/mL}) \times \text{Glucose (fasting, in mmol/L)} / 22.5$$

In a further table CD4 and HIV-RNA are displayed for patients with HIV only by visit. Additional laboratory data for patients with porphyria cutanea tarda (PCT), liver transplantation or cryoglobulinemia (at baseline) will be displayed in separate tables as well.

Instead of the shift tables mentioned in the study protocol, the number and percentage of subjects with post-baseline values until EoT meeting the specified criteria for Potentially Clinically Significant (PCS) laboratory values (defined in Table 11) will be summarized. A post-baseline value must be more extreme than the baseline value to be considered a PCS finding.

Table 11 Criteria for PCS laboratory values

<u>Laboratory data</u>	<u>Very Low</u>	<u>Very High</u>
Laboratory hematology		
Hemoglobin [g/L]	<80	
Platelets [$10^9/L$]	<50	
Laboratory clinical chemistry		
ALT		>5 x ULN and >= 2 x baseline
AST		>5 x ULN and >= 2 x baseline
Creatinine [$\mu\text{mol}/\text{L}$]		>132.605
Creatinine clearance [mL/min]***	<50	
Laboratory metabolic profile		
Fasting glucose [mmol/L]	<2.2	>13.9
Fasting cholesterol [mmol/L]		>10.34
Fasting triglycerides [mmol/L]		>5.7

*** estimated by Cockcroft-Gault-Formula (see above)

Additionally, for hemoglobin and creatinine clearance, the number and percentage of subjects with a maximum Common Terminology Criteria for Adverse Events (CTCAE) Grade of 0, 1, 2, 3, or 4 (see definitions in Table 12) at any post-baseline visit (regardless of the baseline value) through the end of treatment (i.e., Final Treatment Value) will be summarized. For the liver function tests (LFTs) of ALT and AST, the number and percentage of subjects in with a maximum CTCAE Grade of 0, 1, 2, 3, or 4 (see definitions in Table 12) at any post-nadir visit through the end of treatment (i.e., Final Treatment Value) will be summarized. Note, for these analyses, the nadir is used for reference (including baseline).

Table 12 Definition of CTCAE Grades 0-4

<u>Laboratory data</u>	<u>Grade 0</u>	<u>Grade 1</u>	<u>Grade 2</u>	<u>Grade 3</u>	<u>Grade 4</u>
ALT	$\leq\text{ULN}$	$\text{>ULN} - 3 \times \text{ULN}$	$> 3 - 5 \times \text{ULN}$	$> 5 - 20 \times \text{ULN}$	$> 20 \times \text{ULN}$
AST	$\leq\text{ULN}$	$\text{>ULN} - 3 \times \text{ULN}$	$> 3 - 5 \times \text{ULN}$	$> 5 - 20 \times \text{ULN}$	$> 20 \times \text{ULN}$
Hemoglobin decreased [g/L]	≥ 130	$< 130 - 100$	$< 100 - 80$	$< 80 - 65$	< 65
Creatinine clearance [mL/min]	≥ 75	$< 75 - 60$	$< 60 - 30$	$< 30 - 15$	< 15

Table 13 Overview of Outputs for Safety Variables

Output Title	Output Short Name	Analysis Population
Exposure to Study Medication by Treatment Regimen and Fibrosis Stage - SP - <country>	tesm_<c>_tf_sp	Safety population
Unintended Medication Error/ Pregnancy by Treatment Regimen and Fibrosis Stage - SP - <country>	tum_<c>_tf_sp	Safety population
Treatment-emergent AEs by Treatment Regimen and Fibrosis Stage - SP - <country>	tae_<c>_tf_sp	Safety population
Serious Treatment-emergent AEs by Treatment Regimen and Fibrosis Stage - SP - <country>	tsae_<c>_tf_sp	Safety population
Non-Serious Treatment-emergent AEs by Treatment Regimen and Fibrosis Stage - SP - <country>	tnsae_<c>_tf_sp	Safety population
Treatment-emergent AEs by Severity by Treatment Regimen and Fibrosis Stage - SP - <country>	taes_<c>_tf_sp	Safety population
Treatment-emergent AEs Leading to Death by Treatment Regimen and Fibrosis Stage - SP - <country>	taed_<c>_tf_sp	Safety population
Treatment-emergent AEs Leading to Hospitalization by Treatment Regimen and Fibrosis Stage - SP - <country>	taeh_<c>_tf_sp	Safety population
Treatment-emergent AEs Possibly Related to ABBVIE Regimen by Treatment Regimen and Fibrosis Stage - SP - <country>	taera_<c>_tf_sp	Safety population
Treatment-emergent AEs Possibly Related to Ribavirin in Patients taking RBV by Treatment Regimen and Fibrosis Stage - SP - <country>	taerr_<c>_tf_sp_RBV	Safety population: patients taking RBV
Treatment-emergent AEs Caused by Medication Error - Paritaprevir/r-Ombitasvir - by Treatment Regimen and Fibrosis Stage - SP - <country>	taempo_<c>_tf_sp	Safety population
Treatment-emergent AEs Caused by Medication Error - Dasabuvir - in Patients taking 3DAA by Treatment Regimen and Fibrosis Stage - SP - <country>	taemd_<c>_tf_sp_3d_aa	Safety population: patients taking 3DAA
Treatment-emergent AEs Leading to Withdrawal of ABBVIE Regimen by Treatment Regimen and Fibrosis Stage - SP - <country>	taewa_<c>_tf_sp	Safety population
Treatment-emergent AEs Leading to Withdrawal of Ribavirin in Patients taking RBV by Treatment Regimen and Fibrosis Stage - SP - <country>	taewr_<c>_tf_sp_RB_V	Safety population: patients taking RBV
Listing of SAEs - SP - <country>	lsae_<c>_sp	Safety population
Glossary for AEs - <country>	tgae_<c>	-
Co-medication by Treatment Regimen and Fibrosis Stage - SP - <country>	tcom_<c>_tf_sp	Safety population
Co-medication by Profile and by Treatment Regimen and Fibrosis Stage - SP - <country>	tcomp_<c>_tf_sp	Safety population
Associated Treated Condition by Treatment Regimen and Fibrosis Stage - SP - <country>	tatc_<c>_tf_sp	Safety population
Associated Treatment Profiles by Medication of Special Interest and by Treatment Regimen and Fibrosis Stage - SP - <country>	tatp_<c>_mtc_sp	Safety population

Herbals Except St. John's Wort, Homeopathics or Other Drugs Taken During Study by Treatment Regimen and Fibrosis Stage - SP - <country> Glossary for Co-medication - <country>	theho_<c>_tf_sp	Safety population	
Laboratory Hematology by Treatment Regimen and Fibrosis Stage - SP - <country>	tgcom_<c> tlh_<c>_tf_sp	- Safety population	
Laboratory Clinical Chemistry by Treatment Regimen and Fibrosis Stage - SP - <country>	tlc_<c>_tf_sp	Safety population	
CD4 and HIV RNA in Patients With HIV by Treatment Regimen and Fibrosis Stage - SP - <country>	tlch_<c>_tf_sp_hiv	Safety population	
Laboratory Metabolic Profile by Treatment Regimen and Fibrosis Stage - SP - <country>	tlmp_<c>_tf_sp	Safety population	
Potentially Clinically Significant Laboratory Values by Treatment Regimen and Fibrosis Stage - SP - <country>	tpcs_<c>_tf_sp	Safety population	
Worst Laboratory Values by Treatment Regimen and Fibrosis Stage - SP - <country>	twlv_<c>_tf_sp	Safety population	
Laboratory Data in Patients With PCT by Treatment Regimen and Fibrosis Stage - SP - <country>	tldp_<c>_tf_sp_pct	Safety population: Patients With PCT	
Laboratory Data in Patients With Liver Transplantation by Treatment Regimen and Fibrosis Stage - SP - <country>	tltd_<c>_tf_sp_tp	Safety population: Liver Transplantation Patients	
Laboratory Data in Patients With Cryoglobulinemia by Treatment Regimen and Fibrosis Stage - SP - <country>	tldc_<c>_tf_sp_cg	Safety population. Patients With Cryoglobulinemia	

The layouts of the tables mentioned above are provided in Part II of the SAP (Table Shells).

4.2.9 Interim Analyses

4.2.9.1 First Interim Analysis

The first part of the first interim analysis (IA) was performed in May 2016 (data snapshot: 2 May 2016).

Site information and researcher experience were displayed, as well as patient disposition by genotype and cirrhosis status for the EP.

The CP was restricted to patients with planned treatment duration of 8 or 12 weeks who started DAA treatment before 1st April 2016. The following tables were created for the CP

- treatment regimen
- socio-demographic characteristics
- CHC disease characteristics
- CHC Related laboratory variables at baseline
- other key laboratory variables at baseline
- CHC treatment history in treatment experienced patients
- Co-morbidities and co-infections
- alcohol consumption

- CD4 and HIV-RNA in patients with HIV at baseline

All tables were structured by genotype and cirrhosis status.

The second part of the first interim analysis (IA) was performed in September 2016 (data snapshot: 09 September 2016).

The analyses of the first part were repeated for all patients enrolled until 09 September 2016.

Additionally, the CP was restricted to patients with planned treatment duration of 8 or 12 weeks who started DAA treatment before 1st March 2016. The baseline analyses mentioned above were repeated and in addition the following tables were created:

- Virological Response Rates (restricted to SVR12. Virological response rates will be displayed in patients with an evaluable HCV RNA test result (EVAL) as well.)
- EQ-5D-5L, FIS, BMQ, WPAI, PAM13 (descriptive analyses only)

All tables were structured by genotype and cirrhosis status.

The SP was restricted to patients with planned treatment duration of 8 or 12 weeks who started DAA treatment before 1st March 2016 as well. The following tables were created for the SP

- Treatment-emergent AEs
- Serious Treatment-emergent AEs

All tables were structured by treatment regimen and cirrhosis status.

4.2.9.2 Second Interim Analysis

A second interim was performed in January 2017.

Site information and researcher experience were displayed, as well as patient disposition by genotype and fibrosis stage for the EP.

The following tables were created for the EP, SP, CP and TP:

- treatment regimen
- socio-demographic characteristics
- CHC disease characteristics
- CHC Related laboratory variables at baseline
- other key laboratory variables at baseline
- CHC treatment history in treatment experienced patients
- Co-morbidities and co-infections
- alcohol consumption
- CD4 and HIV-RNA in patients with HIV at baseline

All tables were structured by genotype and fibrosis stage, except for the EP. For the EP the baseline characteristic were displayed overall.

In addition, the CP and SP were restricted to patients with a planned treatment duration of 8 or 12 weeks who started DAA treatment before 1st May 2016. The patient disposition was displayed.

Furthermore the following tables were created for the restricted CP:

- treatment regimen
- premature termination of treatment and its main reason
- socio-demographic characteristics
- CHC disease characteristics
- CHC Related laboratory variables at baseline
- other key laboratory variables at baseline
- CHC treatment history in treatment experienced patients
- Co-morbidities and co-infections
- alcohol consumption
- CD4 and HIV-RNA in patients with HIV at baseline
- Virological response rates (restricted to SVR12; once in all patients and once in all patients who completed the treatment)
- Relapse rates
- Viral breakthrough
- EQ-5D-5L, FIS, BMQ, WPAI, PAM13 (descriptive statistics only)

Non-response rates were displayed for the CPSFU12 (once in all patients and once in all patients who completed the treatment). All tables were structured by genotype and fibrosis stage.

The following tables were created for the restricted SP:

- treatment regimen
- socio-demographic characteristics
- CHC disease characteristics
- CHC Related laboratory variables at baseline
- other key laboratory variables at baseline
- CHC treatment history in treatment experienced patients
- Co-morbidities and co-infections
- alcohol consumption
- CD4 and HIV-RNA in patients with HIV at baseline
- exposure to study medication
- treatment-emergent AEs
- serious treatment-emergent AEs
- laboratory hematology
- laboratory clinical chemistry
- potentially clinically significant laboratory values
- worst laboratory values

All tables were structured by treatment regimen and fibrosis stage.

4.2.9.3 Third Interim Analysis

A third interim was conducted in March 2017.

For the third interim analysis the restricted CP and SP were restricted to patients with a planned treatment duration of 8 or 12 weeks who started DAA treatment before 1st July 2016.

The same tables as for the second IA were created.

4.2.10 Protocol Violations and Deviations

Enrolled patients who are excluded from the analysis populations will be summarized and the reasons listed (see section 4.2.1).

5 Data Quality Assurance

Data for this study will be recorded in English by each participating center via an electronic data capture (EDC) system using a web-based eCRF.

A comprehensive data validation program utilizing front-end checks in the eCRF will validate the data. Automated checks for data consistency will be implemented. Discrepancies need to be solved by the researcher in the eCRF before the module can be completed.

Follow-up on eCRF data for medical plausibility will be done by ABBVIE personnel (or their representatives). Queries will be generated in the eCRF for online resolution at the site. The investigator or an authorized member of the investigator's staff will make any necessary data corrections to the eCRF. All change information, including the date and person performing the corrections, will be available via the audit trail, which is part of the EDC system. The principal investigator of each site will finally review the eCRFs for completeness and accuracy of available data and provide his or her electronic signature and date to the eCRFs as evidence thereof.

All statistical programs employed in the analysis and reporting of the data will be validated according to the standard operating procedures of IST and results will be checked for plausibility.

6 Methods of Data Analysis and Presentation

All statistical analyses will be carried out by means of the SAS® package (Version 9.4).

6.1 Analysis Data Sets

A value added dataset STRATIFY will be programmed. This will contain derived variables, e.g. analysis populations, treatment regimen and relevant baseline characteristics, needed for the generation of the planned analyses.

A value added dataset SITES will be programmed. This will contain site information and researcher experience needed for the generation of the planned analyses.

Additional value added dataset will be programmed for the primary and secondary endpoints.

6.2 SAS Output Format

Detailed descriptions of the SAS outputs are given in Part II of the SAP (Table Shells).

7 References

1. Wai C-T, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *HEPATOLOGY* 2003; 38:518-526.
2. Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., Messinger, D. and Nelson, M., Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology* 2006, 43: 1317–1325.
3. EQ-5D-5L User Guide; Basic information on how to use the EQ-5D-5L instrument. Prepared by Mandy Oemar / Bas Janssen. Version 2.0; October 2013
4. Reilly Associates: WPAI Scoring. http://www.reillyassociates.net/WPAI_Scoring.html. 17.09.2015
5. Zill, J. M., Dwinger, S., Kriston, L., Rohenkohl, A., Härter, M. and Dirmaier, J., Psychometric evaluation of the German version of the patient activation measure (PAM13), *BMC Public Health* 2013 , 13:1027
6. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. *Clin Infect Dis*. 1994 Jan;18 Suppl 1:S79-83